Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL8539074 | 0.96 | RXRA (0.43) | RXRARXRBRXRGNOTUMACP1 | |
| SCHEMBL3558741 | 0.89 | RXRA (0.39) | RXRARXRBRXRGNOTUMACP1 | |
| SCHEMBL265486 | 0.84 | IDO1 (0.52) | RXRARXRBRXRGPRKCAPRKCD | |
| SCHEMBL3985022 | 0.84 | NOTUM (0.41) | RXRARXRBRXRGNOTUMACP1 | |
| SCHEMBL25368340 | 0.83 | NOTUM (0.40) | RXRARXRBRXRGNOTUMACP1 | |
| SCHEMBL3591051 | 0.81 | IDO1 (0.41) | NOTUMACP1IDO1TAS2R14CNR1 | |
| SCHEMBL29738521 | 0.81 | IDO1 (0.41) | NOTUMACP1IDO1TAS2R14CNR1 | |
| SCHEMBL14445400 | 0.79 | IDO1 (0.44) | NOTUMACP1IDO1TAS2R14S1PR1 | |
| SCHEMBL6467338 | 0.79 | NOTUM (0.51) | NOTUMACP1IDO1TAS2R14S1PR1 | |
| SCHEMBL17994035 | 0.79 | NOTUM (0.40) | NOTUMACP1IDO1TAS2R14CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2024-04-18 | — | — | US | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| CN-1942428-A | CETP inhibitors | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-5830892-A | Piperidine and morphonline derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 1998-11-03 | — | — | US | disclosed |
| EP-0835253-A1 | PIPERIDINE AND MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001553-A1 | PIPERIDINE AND MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | RXRA 1841/4885RXRB 1737/4885RXRG 2071/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | RXRA 1048/4885RXRB 940/4885RXRG 911/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | RXRA 1797/4885RXRB 1403/4885RXRG 1552/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | RXRA 1797/4885RXRB 1403/4885RXRG 1552/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | RXRA 1797/4885RXRB 1403/4885RXRG 1552/4885 |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | RXRA 530/4885RXRB 454/4885RXRG 426/4885 |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | RXRA 1841/4885RXRB 1737/4885RXRG 2071/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | RXRA 2235/4885RXRB 1616/4885RXRG 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.